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This study compared propranolol alone with a combi-
nation of propranolol and verapamil in patients with
severe, limiting angina of effort. Accordingly, 13 men
(average age 57 years) with severe angina were enrolled
in a study of 7 weeks' duration. Throughout the study,
a stable dose of propranolol (295 ± 83 [mean ± stan-
dard deviation] mglday) was administered. In addition
to propranolol therapy, each patient was given 2 weeks
of up-titration of open label verapamil, 1 week of verap-
amil down-titration and two 2 week periods of random-
ized, double-blind therapy, one of placebo and the other
of verapamil (431 ± 77 mglday). A propranolol-verap-
amil combination caused a decline in anginal episodes/
week (7.3 ± 6.9/week during propranolol-placebo, 4.7
± 5.0/week during propranolol-verapamil, p = 0.03)
and nitroglycerin tablets used/week (7.6 ± 6.6/week
during propranolol-placebo, 4.4 ± 4.2/week during pro-
pranolol-verapamil, p = 0.008). With propranolol-pla-
cebo, all 13 patients had angina after 4.6 ± 2.1 minutes
of supine bicycle exercise. With propranolol-verapamil,
The beta-adrenergic blocking agent s, such as propranolol.
are highly effective in the treatment of patients with stable
angina pectoris (1-9) . By reducing myocardial oxygen de-
mand , these drugs reduce anginal frequency and increase
exercise tolerance in most patients with angina of effort.
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five had no angina with exercise even though their du-
ration of exercise increased; in the other eight, time to
angina increased (from 4.0 ± 1.5 minutes with pro-
pranolol-placebo to 5.3 ± 1.6 minutes with propranolol-
verapamil, p = 0.01).
A propranolol-verapamil combination induced no
change in rest or peak exercise left ventricular volumes
or ejection fraction (assessed by equilibrium gated blood
pool scintigraphy). With propranolol-verapamil, four
patients had PR interval prolongation, and two had fa-
tigue and dyspnea. In addition, two had marked sinus
bradycardia with junctional escape rhythm that was re-
solved with a reduction of verapamil dosage. No patient
developed congestive heart failure or high degree atrio-
ventricular block. Thus, a combination of propranolol
and verapamil is superior to propranolol alone in pa-
tients with severe, limiting angina, but such a combi-
nation must be used cautiously because of potentially
serious adverse effects.
However, because some individuals continue to have lim-
iting angina despite substantial amounts of propranolol , they
may require additional medical therapy . Several studies (10-
14) have demonstrated that verapamil, a calcium antagonist ,
exert s a salutary effect in patient s with angina of effort , and
a recent assessment (15) has shown that the combination of
propranolol and verapamil prolon gs exercise duration in
hospitalized patients with severe angina. However, previous
studies have not evaluated the efficacy and safety of a pro-
pranolol-verapamil combination in a randomi zed, double-
blind study design , nor have they assessed this drug com-
bination in an outpatient setting. The present study com-
pared propranolol alone with a propranolol-verapamil com-
bination in a randomized , double-blind trial involving a
group of ambulatory patients with severe , limiting angina
despite large doses of propranolol.
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Methods
Study Patients
The study population consisted of 13 men with an average age
of 57 years (range 47 to 68). All had severe angina of effort despite
a maximal tolerated dose of propranolol (295 ± 83 [mean ±
standard deviation] mg/day; range 160 to 480). Selective coronary
arteriography revealed significant coronary artery disease (defined
as 2: 70% luminal diameter narrowing) in all patients (triple vessel
in II, double vessel in I, single vessel in I); 7 had undergone
coronary artery bypass surgery in the remote past. Prior to en-
rollment, all patients had a positive exercise tolerance test, with
angina and at least I mm of ST segment depression at peak exercise.
Two of the 13 patients were maintained throughout the study
on a stable dose of oral isosorbide dinitrate (150 and 200 mg/day);
in these individuals, several attempts to taper or discontinue long-
acting nitrates resulted in a marked worsening of angina. One
patient was maintained on digoxin and quinidine therapy for the
control of supraventricular tachyarrhythmias. With these excep-
tions, no other cardiac medications were administered during the
study.
Patients with any ofthe following were excludedfrom the study:
congestive heart failure; uncontrolled systemic arterial hyperten-
sion; hypotension; associated valvular or congenital cardiac dIS-
ease; renal or hepatic disease; any terminal illness; certain elec-
trocardiographic abnormalities, including severe bradycardia,
atrioventricular block of any degree, or atrial flutter or fibrillation;
or concomitant therapy with disopyramide or another investiga-
tional agent.
Study Design (Fig. 1)
All 13 patients entered the study receiving large doses of pro-
pranolol; this dosage was administered during the entire 7 week
study. After informed consent was obtained, each was begun on
treatment with open label verapamil. During a 2 week up-titration
period, the maximal dose of verapamil that did not cause adverse
effects was determined. Specifically, each patient was initially
given 120 mg/day (40 mg, 3 times daily) of verapamil for 3 days,
at which time he was seen by one of the investigators, and a 12
lead electrocardiogram was performed. Subsequently, at 3 day
intervals, the dose of verapamil was increased to 160, 240, 320
Figure 1. Schematic outline of the study design. All patients entered the
study with severe, limiting angina despite propranolol therapy. After a 2
week up-titration and a I week down-titration period of open label vera-
pamil, each patient was randomly assigned to one of two groups for the
remaining 4 weeks of the study. 2 weeks of propranolol-placebo, 2 weeks
of propranolol-verapamil. These 4 weeks of combination therapy were
double-blind.
and 480 mg/day. With each increase in verapamil dosage, the
patient was interviewed and examined, and a 12 lead electrocar-
diogram was recorded. In this manner, the maximal tolerated dos-
age of verapamil was determined for each patient and was em-
ployed during the blinded portion of the study.
After a J week period of down-titration of verapamil, each
patient was randomly assigned to one of two groups for the re-
maining 4 weeks of the study (Fig. J): two 2 week periods of a
propranolol-placebo combination and a propranolol-verapamil
combination. During this period, placebo and verapamil were ad-
ministered in a double-blind fashion, so that neither the physicians
nor the patients knew which agent was being given. In short, these
4 weeks of randomized, double-blind therapy allowed a direct
comparison of the maximal tolerated dose of propranolol alone
and the maximal tolerated doses of propranolol and verapamil in
combination.
Variables Analyzed
Clinical response to therapy. Each of the patients was seen
weekly by one of the investigators, and the following were quan-
titated: (I) episodes of angina per week (recorded daily by the
patient in a diary), (2) nitroglycerin tablets used per week (assessed
by tablet counts), and (3) adverse effects (recorded by the patient
in a diary). During both periods of blinded therapy, ambulatory
electrocardiographic (Holter) monitoring was performed for 24
hours, and the tapes were analyzed for arrhythmias and conduction
disturbances.
Exercise tolerance testing. Near the end of both 2 week pe-
riods of blinded therapy, maximal supine bicycle exercise testing
with simultaneous equilibrium gated blood pool scintigraphy was
performed 90 to 120 minutes after a regularly scheduled dose of
propranolol and study medication. Rest and exercise electrocar-
diograms were monitored with a truncal 12 lead system. Exercise
was commenced at 150 kilipond-meters (kp-rn) per minute and
increased incrementally by 150 kp-rn every 4 minutes until one of
the following occurred: (I) exhaustion, (2) angina of at least mod-
erate severity, or (3) frequent ventricular ectopy. From each ex-
ercise test, the following were quantitated: (I) the clinical response
to exercise, as reflected by the time to onset of angina and the
total duration of exercise; (2) the hemodynamic response to ex-
ercise, as assessed by the heart rate and heart rate-systolic artenal
pressure (rate-pressure) product both at rest and during exercise;
(3) the electrocardiographic response to exercise, as assessed by
the magnitude of ST segment depression at peak exercise in com-
parison with that at rest; and (4) the scmtigraphic response to
exercise, as reflected by left ventricular end-diastolic and end-
systolic volumes and ejection fraction at rest and dunng exercise,
as previously described (14,16-22).
Data Analysis
All patient diaries, nitroglycerin tablet counts, Holter monitor
recordings and exercise tolerance tests were analyzed without
knowledge of the order in which placebo and verapamil were
administered. The clinical characteristics of the patients initially
assigned to placebo were compared with those of the patients
initially assigned to verapamil: there were no differences, con-
firming that the initial assignment was random. For each variable,
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a paired t test and Wilcoxon matched pairs signedranks test were
used to compare propranolol-placebo therapy with propranolol-
verapamil therapy, In comparing rest and peak exercise values
during treatment with the same pharmacologic agent, the paired
t test was used, For all analyses, a probability (p) value of 0,05
or less was considered significant (23,24),
Results
Drug Compliance and Dosage
Compliance (assessed by actual tablet counts) averaged
97% (range 82 to 100%) during propranolol-placebo therapy
and 96% (range 75 to 100%) (difference not significant
[NS]) during propranolol-verapamil therapy. The 13patients
received a mean (± standard deviation) of 431 ± 77 (range
320 to 480) mg/day of verapami!. In each patient, serum
concentrations of propranolol and verapamil were measured
90 to 120 minutes after a regularly scheduled dose of study
medication, For the 13 patients, the serum propranolol level
averaged 87 ± 66 (range 14 to 220) ng/ml, the serum ve-
rapamil concentration 171 ± 114 (range 22 to SOl) ng/ml,
and the serum norverapamil concentration 171 ± 63 (range
40 to 288) ng/m!.
Clinical Response to Therapy
During treatment with propranolol-placebo, the 13 pa-
tients had an average of 7.3 ± 6,9 episodes of angina/week
and used 7,6 ± 6.6 nitroglycerin tablets/week. During pro-
pranolol-verapamil therapy, anginal frequency decreased to
4.7 ± 5.0 episodes/week (p = 0.03) and nitroglycerin
usage to 4.4 ± 4.2 tablets/week (p = 0,008) (Fig. 2),
During propranolol-placebo therapy, two patients com-
plained of fatigue. During verapamil administration (open
label or blinded), six patients noted adverse effects: four
had constipation, two had fatigue and dyspnea and one had
Figure 2. Number of episodes of chest pam/week (left) and the number
of nitroglycerin tablets used/week (right) dunng propranolol-placebo and
propranolol-verapamil therapy. Each line represents the data from one
patient, and the means ± 1 standard deviation are displayed on either side
of each set of lines, During propranolol-verapamil therapy, the number of
episodes of chest pain and nitroglycerin tablets consumed was lower than
dunng propranolol-placebo therapy,
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palpitation and weakness (coincident with a marked sinus
bradycardia and a junctional escape rhythm at 40/min on
Holter monitor), During propranolol-verapamil therapy, four
patients had asymptomatic prolongation of the PR interval
from :::;0.20 to >0,20 second (range 0,21 to 0,26 second),
No patient developed second or third degree heart block or
objective evidence of left ventricular failure.
One of the 13 patients had substantially depressed left
ventricular systolic function, This 59 year old man with
severe three vessel coronary artery disease and previous
coronary bypass surgery had a left ventricular ejection frac-
tion during propranolol-placebo therapy (320 mg/day) of
0.27 at rest and 0,31 with exercise. During this treatment
period, he averaged 22 episodes of angina/week and used
II nitroglycerin tablets/week, With propranolol-verapamil
(320 mg/day of each), his anginal frequency and nitroglyc-
erin usage decreased slightly (18.5 and 9/week, respec-
tively). His left ventricular ejection fraction was 0,25 at rest
and 0.21 with exercise, This patient experienced no adverse
effects during the study,
One serious adverse effect occurred during the study,
An increase in verapamil dosage from 320 to 480 mg/day
during the open label up-titration period caused one patient
to be hospitalized for angina coincident with a junctional
rhythm at a rate of 35 beats/min, There was no evidence of
myocardial infarction, and sinus rhythm returned after the
verapamil dose was reduced to 320 mg/day. Subsequently,
this patient completed the study without further adverse
reactions,
Exercise Tolerance Testing
Symptomatic response to exercise. During propran-
olol-placebo therapy, all 13 patients developed angina after
an average of4.6 ± 2,1 (range2to 10) minutes of exercise.
With propranolol-verapamil, five patients exercised to fa-
tigue without angina, even though exercise duration for
these five increased from 7.4 ± 3, I minutes with propran-
olol-placebo to 10,3 ± 3, I minutes with propranolol-ve-
rapamil (p < 0.0 I), In the remaining eight patients, exercise
time to angina increased from 4.0 ± 1,5 minutes on pro-
pranolol-placebo to 5.3 ± 1.6 minutes on propranolol-ve-
rapamil (p = 0,01). For all 13 patients, the total exercise
duration was 6,8 ± 2.4 minutes on propranolol-placebo and
8,2 ± 2,9 minutes on propranolol-verapamil (p < 0,05)
(Table I),
Hemodynamic response to exercise (Fig. 3). The ad-
dition of verapamil to propranolol did not cause a significant
change in rest heart rate, systolic arterial pressure or rate-
pressure product (Table I, Fig, 3), At peak exercise, heart
rate was lower (p = 0,03) during propranolol-verapamil
than during propranolol-placebo therapy (Fig, 3), Systolic
arterial pressure at peak exercise was similar during both
treatment periods, Because of the lower heart rate at peak
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Table 1. Clinical, Hemodynamic and Scintigraphic Variables
During Exercise Tolerance Testing
Propranolol + Propranolol +
Placebo Veraparml
6.g ± 2.4 82 ± 2.9*
57 ± 5 56 ± 6
82 ± g 76 ± 9*
136 ± 25 130 ± 20
159 ± 31 151 ± 23
Figure 3. Heart rate at rest (top left) and at peak exercise (bottom left),
a, well as heart rate-systolic blood pressure product at rest (top right) and
at peak exercise (bottom right) dunng each of the two treatment penods.
Each line represents the data from one patient, and the means ± I standard
deviation are displayed on either side of each set of lmes. At rest, heart
rate and rate-pressure product were similar during both treatment penods.
With exercise, propranolol-verapamil reduced both variables.
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Figure 4. Left ventricular ejecuon fraction at rest (left) and at peak ex-
ercise (right) dunng the two treatment penods. Each line represents the
data from one patient, and the means ± I standard deviation are displayed
on either side of each set of lines. The combination of propranolol and
veraparml exerted no effect on either rest or peak exercise ejection fracuon.
exert a salutary effect in patients with angina of effort, their
combined administration may be especially effective in pa-
tients whose angina is limiting despite administration of
large doses of only one agent. Indeed, the present random-
ized and double-blind assessment demonstrates that a pro-
pranolol-verapamil combination is superior to propranolol
alone in patients with severe angina.
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exercise during propranolol-verapamil therapy, the rate-
pressure product at peak exercise was lower during such
combination therapy (Table L Fig. 3).
Electrocardiographic response to exercise. During
therapy with propranolol-placebo, the 13 patients had 0.13
± 0.09 mY of ST segment depression at peak exercise.
During propranolol-verapamil therapy, these patients had
only 0.08 ± 0.08 mY of ST segment depression (p =
0.007), even though (as mentioned previously) exercise du-
ration increased during combination therapy.
Scintigraphic response to exercise (Fig. 4). At rest and
peak exercise, left-ventricular end-diastolic volume index,
end-systolic volume index and ejection fraction were similar
during the propranolol-placebo and propranolol-verapamil
treatment periods (Table I, Fig. 4).
Values are expressed a' mean value, :t standard devianon
*p < 0 05 In comparison with propranolol + placebo
LVEDVI = left ventncular end-diastohc volume mdex, LVEF = lett ventncular
ejection fraction. LVESVI = left ventricular end-vy-tohc volume mdex
Discussion
Over the past two decades, propranolol has proved highly
effective in the therapy of patients with angina of effort (1-
9), and verapamil has been shown to be similarly beneficial
in patients with this syndrome (10-14). Because both drugs
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Antianginal mechanisms of propranolol and verapa-
mil. Propranolol exerts antianginal effects in several ways,
Most importantly, it diminishes myocardial oxygen de-
mands by reducing the three major determinants of myo-
cardial oxygen consumption-heart rate, systemic arterial
pressure and left ventricular contractility (25-27). In ad-
dition, propranolol may inhibit enhanced platelet aggrega-
tion (28) and may increase tissue oxygen delivery by altering
the affinity of hemoglobin for oxygen (29). It does not
induce coronary artery dilation and, therefore, does not exert
a salutary effect on coronary blood flow. In fact, in patients
in whom coronary artery spasm is of etiologic importance,
propranolol may actually cause coronary artery vasocon-
striction (30). The beneficial effect of verapamil in patients
with angina of effort is accomplished first by a reduction in
myocardial oxygen requirements. Similar to propranolol,
this agent diminishes heart rate, systemic arterial pressure
and left venticular contractility (31,32). Second, in contrast
to propranolol, verapamil reduces coronary vascular resis-
tance and, as a result, may augment both anterograde (33)
and retrograde (34) coronary blood flow.
Because propranolol and verapamil differ somewhat in
their antianginal mechanisms, their combined administra-
tion may exert an especially beneficial effect. For example,
the increase in sympathetic tone occurring in response to
verapamil-induced peripheral vasodilation may be blunted
by propranolol, thus allowing a marked reduction in left
ventricular contractility and myocardial oxygen demand.
Alternatively, the propensity of propranolol to increase cor-
onary vascular resistance in patients in whom coronary ar-
tery spasm is operative (30) is effectively countered by the
direct vasodilating influence of verapamil. Finally, it is con-
ceivable that a propranolol-verapamil combination is es-
pecially salutary in patients with angina because one of the
two agents in some way induces a pharmacokinetic poten-
tiation of the other. Whatever the exact mechanism(s), a
propranolol-verapamil combination may exert a more powerful
antianginal effect than either agent alone.
In the present study, the combined administration of pro-
pranolol and verapamil did not alter rest heart rate or heart
rate-systolic arterial pressure product in comparison with
propranolol therapy alone. However, at peak exercise, the
drug combination lowered both variables (Fig. 3), reflecting
a further reduction in myocardial oxygen requirements. It
is unknown whether such combination therapy exerted any
effect on myocardial oxygen supply.
Beneficial effects of a propranolol-verapamil combi-
nation. In a single-blind assessment of II hospitalized pa-
tients with severe angina pectoris, Leon et al. (15) showed
that a propranolol-verapamil combination was more effec-
tive than either agent alone in increasing exercise time and
in either delaying or ablating the occurrence of exercise-
induced angina. Similar results subsequently have been re-
ported by Subramanian et al. (35). The present randomized,
double-blind study of 13 ambulatory outpatients with se-
vere, limiting angina shows that a propranolol-verapamil
combination is superior to propranolol alone. Such com-
bination therapy reduced the frequency of angina and the
usage of sublingual nitroglycerin (Fig. 2). It increased both
exercise duration and the time from onset of exercise to
appearance of chest pain, and in five patients, it totally
alleviated exercise-induced angina. Left ventricular volumes
and ejection fraction, measured both at rest and during su-
pine bicycle exercise, were not affected detrimentally by
the propranolol-verapamil combination (Fig. 4). In short, a
propranolol-verapamil combination was more effective than
propranolol alone in diminishing symptoms and increasing
exercise capability.
Adverse effects of a propranolol-verapamil combi-
nation. The combination of propranolol and verapamil may
produce serious adverse effects, and anecdotal reports (36-
39) have described cardiovascular catastrophes when intra-
venous verapamil was administered to patients already re-
ceiving propranolol. Because both agents exert negative
inotropic and chronotropic effects, their combined usage
may induce left ventricular failure, marked bradycardia or
atrioventricular block. In addition, several recent investi-
gations (40-43) have demonstrated that the acute admin-
istration of verapamil to patients already receiving propran-
olol induces no change or deterioration in cardiac output,
left ventricular ejection fraction, intracardiac filling pres-
sures and atrio-His conduction. Of the II patients reported
by Leon et al. (15), combined propranolol-verapamil ther-
apy caused PR interval prolongation in most, transient
Wenckebach block in I and dyspnea, orthostatic dizziness
and pedal edema in 3.
In the present study, no patient developed symptoms or
signs of left ventricular failure during combination therapy,
and multigated blood pool scintigraphy demonstrated no
deterioration of left ventricular systolic performance (Table
I, Fig. 4). Although four patients developed first degree
atrioventricular block, none had second or third degree block.
Two patients had episodes of marked sinus bradycardia with
junctional escape rhythm, one of which was associated with
prolonged angina. Although the incidence of adverse effects
was small in this study, it should be emphasized that pa-
tients with congestive heart failure or conduction system
disease were excluded from enrollment and that the up-
titration of verapamil was performed slowly and carefully,
thus minimizing the chance that combination therapy would
cause serious adverse effects. Therefore, propranolol and
verapamil should be administered concomitantly with great
caution.
Advantages and limitations of the present study. There
are several strengths to the present study. First, it is a ran-
domized and double-blind comparison of propranolol alone
and a propranolol-verapamil combination, Second, because
the 13 study patients had severe, limiting angina despite
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maximal tolerated dosages of propranolol, they closely re-
semble those in whom combination therapy is most seriously
considered. Third, the entire study was performed in a group
of ambulatory outpatients in whom hospitalization was not
employed, even for the verapamil up-titration period. Fourth,
in each patient, the maximal tolerated dosage of propranolol
was compared with the maximal tolerated dosage of both
propranolol and verapamil; that is, the study was designed
to compare maximal tolerated-rather than fixed-dosages
of each agent.
The present study also has certain limitations. Thirteen
patients is not a large number, and, therefore, our results
will require confirmation in a greater number of patients.
All 13 patients were male; women will probably respond
similarly when given a propranolol-verapamil combination,
but this, too, will require confirmation. Although the present
study demonstrates that a propranolol-verapamil combina-
tion is superior to propranolol alone, it does not compare
either therapy with verapamil alone. Because Frishman et
al. (44) have suggested that verapamil is superior to pro-
pranolol, it is conceivable that the efficacy of combination
propranolol-verapamil therapy may be similar to that of
verapamil alone. Finally, because each blinded treatment
period lasted only 14 days, the long-term efficacy and safety
of combined propranolol-verapamil therapy cannot be as-
sessed from these data.
Conclusions. In patients with severe, limiting angina
despite large doses of propranolol, a propranolol-verapamil
combination is effective in relieving angina, reducing ni-
troglycerin usage and increasing exercise capability. When
such combination therapy is administered carefully, it ap-
pears reasonably safe, although an occasional patient may
develop symptomatic bradycardia or heart block.
We acknowledge the assistance of Kay Lancaster and R. Scott Lyons In
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